GeoVax Labs Advances GEO-MVA Vaccine Development Amid Rising Global Mpox Threat

GeoVax Labs, Inc. is making significant progress in the development of its GEO-MVA vaccine, aimed at combating the growing global threat posed by Mpox and smallpox. The European Medicines Agency (EMA) has provided positive regulatory feedback, accelerating the vaccine's path to market access. This advancement underscores the critical need to address public health demands and broaden the spectrum of vaccine supply options available worldwide.

The GEO-MVA vaccine, leveraging GeoVax's innovative platform, offers improved production efficiency and the agility to respond to outbreaks promptly. This is particularly relevant as Mpox cases surge across the United States, Europe, and regions of Africa, highlighting the necessity for comprehensive stockpile strategies and alternative vaccine options. David Dodd, Chairman and CEO of GeoVax, stressed the significance of diversifying the MVA-vaccine supply to enhance global public health outcomes.

Recent milestones, including favorable Scientific Advice from the EMA and a proposal under the Biomedical Advanced Research and Development Authority’s (BARDA) Rapid Response Partnership Vehicle (RRPV), have positioned the GEO-MVA vaccine as a promising candidate for pandemic preparedness and biodefense. These developments not only facilitate the vaccine's rapid advancement but also pave the way for potential revenue streams, marking a crucial step in GeoVax's mission to commercialize its vaccine and make a lasting impact on public health.

For more information on GeoVax's efforts and the GEO-MVA vaccine, visit https://www.geovax.com.